ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2694

Treatment of ZAP-70 Mutant SKG Mice with Anti-IL-23 Antibody Alters Fecal Microbiota Composition and Prevents Outgrowth of Bacteria Associated with Susceptibility to Spondyloarthritis and Ileitis

Linda Rehaume1, Nicholas Matigian1, Alicia Kang1, Olga Zbarskaya1, Kristine Kikly2, Nancy Lachner3, Joshua Daly3, Philip Hugenholtz3, Mark Morrison1, Kim-Anh Lê Cao4 and Ranjeny Thomas1, 1Translational Research Institute, The University of Queensland Diamantina Institute, Brisbane, Australia, 2Biotechnology Discovery Research, Eli Lilly and Co, Indianapolis, IN, 3The University of Queensland, Australian Centre for Ecogenomics, Brisbane, Australia, 4Translational Research Instiute, The University of Queensland Diamantina Institute, Brisbane, Australia

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: IL-23, inflammatory bowel disease (IBD), microbiome, mouse model and spondylarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Identification of disease-associated or protective bacteria may elucidate new biomarkers or probiotic supplements for people suffering from spondyloarthritis (SpA), or for people at-risk of disease development. The colitogenic Prevotella copri was associated with new-onset rheumatoid arthritis, and Prevotella spp. were increased in the cecum of HLA-B27 transgenic rats. Ankylosing spondylitis patients have increases in several bacterial families including Porphyromonadaceae. Lactobacillus murinus is protective in a murine model of colitis. Thus, microbes are associated with SpA disease progression but it is unclear how the microbial community structure differs as a result of genetic susceptibility to SpA, or the impact of additional pro-inflammatory triggers or drivers. Since IL-23 is a key driver of SpA, we hypothesized that IL-23 modifies the gut microbiota and the response to pro-inflammatory triggers of SpA.

Methods: BALB/c ZAP-70W163C-mutant (SKG) mice housed under specific pathogen-free (SPF) conditions treated with microbial β-1,3-glucan (curdlan) develop IL-23- and microbiota-dependent SpA-like arthritis and ileitis. Altered Schaedler flora(ASF)-colonized SKG and BALB/c mice were treated one day prior to curdlan, and then weekly, with anti-IL-23 p19-specific mAb or isotype control mAb, or with curdlan or vehicle control. SPF-SKG mice were treated weekly with anti-IL-23 or isotype mAb for 3 weeks, then with curdlan or vehicle control. Fecal samples were collected longitudinally and the microbiota community profiles were analyzed by RT-PCR and next-generation sequencing. Arthritis, spondylitis and ileitis were assessed histologically.

Results: After colonization of germ-free mice with ASF, 4/8 bacterial strains were detected in ASF-SKG and ASF-BALB/c mice: Clostridium sp., Lactobacillus murinus, Mucispirillum schaedleri and Parabacteroides sp. Whilst the relative abundance of Clostridium sp. and Parabacteroides sp. was decreased in SKG, the most abundant bacterial species in both strains of mice was the Parabacteroides sp. After curdlan, the abundance of L. murinus and M. schaedleri but not Parabacteroides sp. declined in ASF-SKG mice over time, while the abundance of L. murinus and M. schaedleri did not decline in mice treated with curdlan and anti-IL-23 mAb. In SPF-SKG mice treated with anti-IL-23 mAb or anti-IL-23 mAb then curdlan, the abundance of multiple Prevotellaceae and Porphyromonadaceae spp. decreased relative to SPF-SKG mice treated with isotype then curdlan.

Conclusion: Interaction of the microbiota with the immune system of SKG mice alters the composition of both a simplified consortium and an unrestricted bacterial community. Curdlan triggers the decline of a gut-protective species within a simplified consortium. Treatment of SPF-SKG mice with anti-IL-23 mAb not only suppresses SpA development but shifts the fecal microbiota composition and prevents the usual outgrowth of bacteria associated with arthritis and inflammatory bowel disease in response to curdlan.


Disclosure: L. Rehaume, None; N. Matigian, None; A. Kang, None; O. Zbarskaya, None; K. Kikly, None; N. Lachner, None; J. Daly, None; P. Hugenholtz, None; M. Morrison, None; K. A. Lê Cao, None; R. Thomas, None.

To cite this abstract in AMA style:

Rehaume L, Matigian N, Kang A, Zbarskaya O, Kikly K, Lachner N, Daly J, Hugenholtz P, Morrison M, Lê Cao KA, Thomas R. Treatment of ZAP-70 Mutant SKG Mice with Anti-IL-23 Antibody Alters Fecal Microbiota Composition and Prevents Outgrowth of Bacteria Associated with Susceptibility to Spondyloarthritis and Ileitis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/treatment-of-zap-70-mutant-skg-mice-with-anti-il-23-antibody-alters-fecal-microbiota-composition-and-prevents-outgrowth-of-bacteria-associated-with-susceptibility-to-spondyloarthritis-and-ileitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-of-zap-70-mutant-skg-mice-with-anti-il-23-antibody-alters-fecal-microbiota-composition-and-prevents-outgrowth-of-bacteria-associated-with-susceptibility-to-spondyloarthritis-and-ileitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology